Cyclacel Pharmaceuticals (NASDAQ:CYCC) Issues Quarterly Earnings Results

Cyclacel Pharmaceuticals (NASDAQ:CYCC) posted its earnings results on Wednesday. The biotechnology company reported ($0.33) earnings per share for the quarter, Zacks reports. Cyclacel Pharmaceuticals had a negative return on equity of 1,901.11% and a negative net margin of 18,150.00%.

Cyclacel Pharmaceuticals Stock Down 8.8 %

Shares of NASDAQ:CYCC traded down $0.02 during mid-day trading on Wednesday, reaching $0.25. 295,215 shares of the stock were exchanged, compared to its average volume of 1,203,280. Cyclacel Pharmaceuticals has a one year low of $0.23 and a one year high of $4.00. The stock’s 50 day simple moving average is $0.33 and its 200-day simple moving average is $0.50. The company has a market cap of $1.54 million, a P/E ratio of -0.03 and a beta of 0.28.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on Cyclacel Pharmaceuticals in a research note on Monday. They set a “sell” rating for the company.

Insider Buying and Selling

In other Cyclacel Pharmaceuticals news, CEO David E. Lazar sold 194,628,820 shares of the firm’s stock in a transaction on Wednesday, February 26th. The stock was sold at an average price of $0.03, for a total transaction of $5,838,864.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 23.97% of the stock is currently owned by corporate insiders.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.